Locations:
Search
Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin
Oral anticoagulants may be beneficial but need to be balanced against bleeding risks
Findings have implications for reducing venous thromboembolisms
A cost-effective alternative to enoxaparin?
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
An underappreciated immune-related adverse event
Why routine screening isn’t advised despite higher prevalence of venous thromboembolism
Add prophylaxis for patients receiving systemic therapy
Prescreening for clots also effective
Toward an evidence-based approach
Advertisement
Advertisement